The company's commercial launch is struggling to gain traction, as evidenced by a 2026Q2 operating loss of $28.6 million against a modest $1.7 million in revenue.
| Sales/Revenue | 5.61M | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 1.12M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 4.49M | 0 | 0 | 0 | 0 |
| Gross Margin % | 80.07% | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 48.02M | 23.52M | 20.57M | 12.12M | 9.71M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 41.61M | 17.1M | 15.65M | 7.88M | 2.86M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 5.83M | 6.42M | 4.92M | 4.24M | 6.86M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 573.44K | 0 | 0 | 0 | 0 |
| Operating Income | -43.52M | -23.52M | -20.57M | -12.12M | -9.71M |
| Operating Margin % | -775.6% | - | - | - | - |
| Operating Income Growth % | - | -14.34% | -69.72% | -24.79% | - |
| EBITDA | -42.91M | -23.49M | -20.57M | -12.12M | 0 |
| EBITDA Margin % | -764.74% | - | - | - | - |
| EBITDA Growth % | -70.53% | -14.16% | -69.72% | - | - |
| D&A (Non-Cash Add-back) | 573.44K | 0 | 0 | 0 | 9.71M |
| EBIT | -43.46M | -23.49M | -20.57M | -12.12M | -9.71M |
| Net Interest Income | -224.9K | -181.66K | 0 | 0 | 0 |
| Interest Income | 72.01K | 36.37K | 0 | 0 | 0 |
| Interest Expense | 296.9K | 218.03K | 0 | 0 | 0 |
| Other Income/Expense | 1.57M | -181.66K | 0 | 0 | 0 |
| Pretax Income | -41.95M | -23.7M | -20.57M | -12.12M | -9.71M |
| Pretax Margin % | -747.56% | - | - | - | - |
| Income Tax | 561.51K | 1.06M | 576K | 576K | 1.15M |
| Effective Tax Rate % | -1.34% | -4.46% | -2.8% | -4.75% | -11.86% |
| Net Income | -42.51M | -24.76M | -21.15M | -12.7M | -10.87M |
| Net Margin % | -757.57% | - | - | - | - |
| Net Income Growth % | -63.62% | -17.08% | -66.56% | -16.86% | - |
| Net Income (Continuing) | -42.51M | -24.76M | -21.15M | -12.7M | -10.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.43 | -0.34 | -0.30 | -0.19 | -0.08 |
| EPS Growth % | -26.51% | -13.33% | -57.89% | -149.02% | - |
| EPS (Basic) | - | -0.34 | -0.30 | -0.19 | -0.08 |
| Diluted Shares Outstanding | 100.03M | 73.27M | 71.55M | 89.48M | 90.16M |
| Basic Shares Outstanding | 100.03M | 73.27M | 71.55M | 89.48M | 90.16M |
| Dividend Payout Ratio | - | - | - | - | - |
Imminent liquidity shortfall
As reported in recent financial statements, CTOR's revenue trajectory remains highly erratic, with quarterly figures fluctuating from $3.9 million in 2026Q1 to $1.7 million in 2026Q2, highlighting the inherent unpredictability of initial product uptake for its orphan oncology therapeutic in a fragmented hematology-oncology market.
The sharp sequential decline in revenue suggests that the initial launch phase may be struggling to establish a consistent patient base. Investors should monitor whether this volatility reflects genuine demand challenges or merely the lumpy nature of early-stage treatment cycle recognition.
Based on the company's 2026Q2 income statement, SG&A expenses surged to $27.2 million, a significant escalation that dwarfs the $1.7 million in revenue, indicating that the cost of building a dedicated oncology sales force is currently outpacing the firm's ability to generate meaningful top-line returns.
This aggressive spending profile suggests management is prioritizing market penetration over near-term expense discipline. The lack of scale in the current revenue base implies that these fixed commercial costs will continue to exert severe downward pressure on operating margins until patient adoption accelerates significantly.
According to the latest quarterly data, CTOR reported an operating loss of $28.6 million in 2026Q2, demonstrating that the company has yet to achieve any meaningful operating leverage as SG&A costs ballooned while gross profit remained constrained at only $1.3 million for the same period.
The widening gap between gross profit and operating expenses suggests that the business model is currently in a high-burn phase with no immediate path to profitability. Without a substantial increase in treatment volume, the current cost structure appears unsustainable for a standalone entity with limited capital.
As indicated by the company's reported cash position of approximately $3.9 million, CTOR faces a precarious liquidity situation that may necessitate dilutive financing, as the current quarterly operating burn rate of $28.6 million far exceeds the available cash reserves to support ongoing commercial operations.
The reliance on external capital to fund the commercial rollout creates a significant overhang for equity holders. Investors should be wary that the current valuation may not fully account for the high probability of future equity dilution required to sustain the company's operations through the next fiscal year.
Quick answers to the most common questions about buying CTOR stock.
For fiscal year 2025, Citius Oncology, Inc. (CTOR) reported total revenue of $0.0M.
Citius Oncology, Inc. (CTOR) reported a net loss of $24.8M for the fiscal year ending 2025.